Vote of confidence
India's IP regime still has a lot of ground to cover
)
premium
Representative image
The Global Innovation Policy Centre (GIPC) of the US Chamber of Commerce, which compiles the annual global IP Index, has acknowledged appreciable improvement in India’s intellectual property (IP) protection regime. The IP Index 2019, released by it, places India at 36, up eight slots from the previous year’s 44, among 50 world economies which together account for over 90 per cent of the world’s gross domestic product. Significantly, this is for the second year in a row that India’s gain in ranking is the largest among all the countries included in the index that takes into account 45 parameters covering patents, trademarks, copyrights and trade secrets. The Index report concedes that the surge in the score reflects improvement in India’s IP environment as a result of reforms focused sharply at building and sustaining an innovation ecosystem for domestic entrepreneurs and foreign investors alike. The reformist measures cited in the report include accession to IPR-related international treaties; consent to initiate a Patent Prosecution Highway with international offices; dedicated set of IP incentives for small business enterprises; and a strong awareness-raising effort on the negative impact of piracy and counterfeiting.
However, it’s not roses all the way, as the report has red-flagged some areas as problematic, calling for more reforms. The GIPC has pinpointed some issues which, though compatible with the global treaty on Trade-Related Intellectual Property Rights (TRIPs), seem ill-suited to innovation-based businesses looking for perpetuating their patents. The most prominent among these are the provision in the patent law for “compulsory licensing” to allow commercial production of a patented product in public or national interest and an unambiguous definition of patentability that denies extension (read ever-greening) of a patent on trivial grounds. The other purportedly objectionable aspects include barriers to licensing and technology transfer, limited framework for safeguarding bio-pharmaceutical IPRs and lengthy procedure for pre-grant opposition to patents.
However, it’s not roses all the way, as the report has red-flagged some areas as problematic, calling for more reforms. The GIPC has pinpointed some issues which, though compatible with the global treaty on Trade-Related Intellectual Property Rights (TRIPs), seem ill-suited to innovation-based businesses looking for perpetuating their patents. The most prominent among these are the provision in the patent law for “compulsory licensing” to allow commercial production of a patented product in public or national interest and an unambiguous definition of patentability that denies extension (read ever-greening) of a patent on trivial grounds. The other purportedly objectionable aspects include barriers to licensing and technology transfer, limited framework for safeguarding bio-pharmaceutical IPRs and lengthy procedure for pre-grant opposition to patents.